Alzheimer's disease (AD) brains are characterized by accumulation of amyloid b protein (Ab) and neuroinflammation. Increased blood-to-brain influx and decreased brain-to-blood efflux across the bloodbrain barrier (BBB) have been proposed as mechanisms for Ab accumulation. Epidemiological studies suggest that the nonsteroidal anti-inflammatory drug (NSAID) indomethacin slows the progression of AD. We hypothesized that inflammation alters BBB handling of Ab. Mice treated with lipopolysaccharide (LPS) had increased brain influx and decreased brain efflux of Ab, recapitulating the findings in AD. Neither influx nor efflux was mediated by LPS acting directly on BBB cells. Increased influx was mediated by a blood-borne factor, indomethacin-independent, blocked by the triglyceride triolein, and not related to expression of the blood-to-brain transporter of Ab, RAGE. Serum levels of IL-6, IL-10, IL-13, and MCP-1 mirrored changes in Ab influx. Decreased efflux was blocked by indomethacin and accompanied by decreased protein expression of the brain-to-blood transporter of Ab, LRP-1. LPS paradoxically increased expression of neuronal LRP-1, a major source of Ab. Thus, inflammation potentially increases brain levels of Ab by three mechanisms: increased influx, decreased efflux, and increased neuronal production.
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Introduction
Alzheimer's disease (AD) is characterized by elevated levels of amyloid b protein (Ab) in brain (Hardy and Selkoe, 2002 ). However, the increased level of Ab in AD in rarely caused by an overexpression of amyloid precursor protein (APP), but rather by an impaired clearance of Ab from the brain. Most work has focused on altered enzymatic activities as causing this impaired clearance (Selkoe and Wolfe, 2007) , but the blood-brain barrier (BBB) has also been proposed to play a role (Deane et al., 2004b) . Ab is transported by RAGE (receptor for advanced glycation end products) into (Martel et al., 1996; Bell et al., 2006; Deane et al., 2003; Maness et al., 1994) and by LRP-1 (low density lipoprotein receptor-related protein-1) out of (Banks et al., 2003; Deane et al., 2004a; Shibata et al., 2000; Ghersi-Egea et al., 1996 ) the brain. Both increased blood-tobrain transport (LaRue et al., 2004) and impaired brain-to-blood transport of Ab (Deane et al., 2004b) across the blood-brain barrier (BBB) have been proposed to occur in AD. Evidence is particularly strong for the neurovascular hypothesis, which states that decreased Ab clearance by the BBB contributes to Ab accumulation and the progression of AD (Deane et al., 2008) . For example, AD patients as well as animal models of AD have a decreased rate of Ab clearance across the BBB (Banks et al., 2003; Bell et al., 2006; Zlokovic, 2004) and knockdown of LRP-1 expression results in decreased clearance of Ab, increased brain levels of Ab, and cognitive impairments (Jaeger et al., in press ).
The underlying cause of altered handling of Ab by the BBB, however, is unknown. One possible cause could be inflammation. Brains from AD patients are characterized by neuroinflammation, including marked astrocytosis, elevated levels of proinflammatory cytokines, and microglial activation (Butterfield et al., 2001; Morley et al., 2002) . Systemic inflammatory events can induce neuroinflammation in the central nervous system (CNS). For example, intraperitoneal administration of lipopolysaccharide (LPS) results in neuronal death in the ME7 mouse model of prion disease (Combrinck et al., 2002) , increased APP processing and intracellular accumulation of Ab (Sheng et al., 2003) , and altered BBB transport activity (Banks et al., 1999; Xaio et al., 2001) . Epidemiologic
